In recent years, both governments of China and the U.S. have come up with various regulations that may have significant impact on the ability of Chinese technology companies, including pharma and biotech, to raise fund, including IPO, in the U.S. market. The volatile global stock market in 2021 and the first half of 2022, especially for biotech companies, only make the water muddier in the foreseeable future. In this fireside chat, a distinguished panel of experts and thought leaders ranging from biotech equity analyst, portfolio manager, to business consultant and legal counsel will share their insights on how the current developments would impact on the capital market in the pharmaceutical and biotech industries in general, with more focus on the impact on Chinese biotech companies entering the U.S. capital market.

Speakers:
Les Funtleyder, MPH, Chief Investment Officer, Technik Health; Healthcare Portfolio Manager, E Squared Asset Management
James Early, Managing Partner, Tamarack Advisory
Paul B. Edelberg, JD, Partner, Fox Rothschild LLP
Kelly Shi, PhD, MBA, Senior Vice President, Biotechnology Equity Research, Jefferies LLC

Entrepreneurship Crash Course: Sponsored Research Agreement (2:15 pm - 2:35 pm)

Speakers:
Peter J. Butch III, JD, Partner, Fox Rothschild LLP

Please note there may be a cost to attend.